The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Clinical and Molecular Spectrum of Liposarcoma
Open accessAbstract
Liposarcomas are rare malignant tumors of adipocytic differentiation. The classification of liposarcomas into four principal subtypes reflects the distinct clinical behavior, treatment sensitivity, and underlying biology encompassed by these diseases. Increasingly, clinical management decisions and the development of investigational therapeutics are informed by an improved understanding of subtype-specific molecular pathology. Well-differentiated liposarcoma is the most common subtype and is associated with indolent behavior, local recurrence, and insensitivity to radiotherapy and chemotherapy. Dedifferentiated liposarcoma represents focal progression of well-differentiated disease into a more aggressive, metastasizing, and fatal malignancy. Both of these subtypes are characterized by recurrent amplifications within chromosome 12, resulting in the overexpression of disease-driving genes that have been the focus of therapeutic targeting. Myxoid liposarcoma is characterized by a pathognomonic chromosomal translocation that results in an oncogenic fusion protein, whereas pleomorphic liposarcoma is a karyotypically complex and especially poor-prognosis subtype that accounts for less than 10% of liposarcoma diagnoses. A range of novel pharmaceutical agents that aim to target liposarcoma-specific biology are under active investigation and offer hope of adding to the limited available treatment options for recurrent or inoperable disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
WHO Classification of Tumours of Soft Tissue and Bone: WHO Classification of Tumours, vol. 5
Fletcher, C. D. �., Bridge, J., Hogendoorn, P. C. W., & Mertens, F. (2013) · Cited by 3,388
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma
Crozat, A., Åman, P., Mandahl, N., & Ron, D. (1993) · Nature · doi:10.1038/363640a0 · Cited by 894
Demetri, G. D., von Mehren, M., Jones, R. L., Hensley, M. L., Schuetze, S. M., Staddon, A., Milhem, M., Elias, A., Ganjoo, K., Tawbi, H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4734 · Cited by 841
Self-citationSchöffski, P., Chawla, S., Maki, R. G., Italiano, A., Gelderblom, H., Choy, E., Grignani, G., Camargo, V., Bauer, S., Rha, S. Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01283-0 · Cited by 778
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., Shah, K., Socci, N. D., Weir, B. A., Ho, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.619 · Cited by 735
Sleijfer, S., Ray-Coquard, I., Papai, Z., Le Cesne, A., Scurr, M., Schöffski, P., Collin, F., Pandite, L., Marreaud, S., De Brauwer, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3223 · Cited by 679
Singer, S., Antonescu, C. R., Riedel, E., & Brennan, M. F. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000086542.11899.38 · Cited by 670
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.237 · Cited by 653
Henricks, W. H., Chu, Y. C., Goldblum, J. R., & Weiss, S. W. (1997) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199703000-00002 · Cited by 632
Tap, W. D., Jones, R. L., Van Tine, B. A., Chmielowski, B., Elias, A. D., Adkins, D., Agulnik, M., Cooney, M. M., Livingston, M. B., Pennock, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30587-6 · Cited by 584
Self-citationRay-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
Ducimetière, F., Lurkin, A., Ranchère-Vince, D., Decouvelaere, A.-V., Péoc'h, M., Istier, L., Chalabreysse, P., Muller, C., Alberti, L., Bringuier, P.-P., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020294 · Cited by 554
Demetri, G. D., Chawla, S. P., von Mehren, M., Ritch, P., Baker, L. H., Blay, J. Y., Hande, K. R., Keohan, M. L., Samuels, B. L., Schuetze, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0088 · Cited by 538
Gronchi, A., Ferrari, S., Quagliuolo, V., Broto, J. M., Pousa, A. L., Grignani, G., Basso, U., Blay, J.-Y., Tendero, O., Beveridge, R. D., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30334-0 · Cited by 496
Demetri, G. D., Fletcher, C. D. M., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M., & Singer, S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3951 · Cited by 495
Differential sensitivity of liposarcoma subtypes to chemotherapy
Jones, R. L., Fisher, C., Al-Muderis, O., & Judson, I. R. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.07.023 · Cited by 354
Self-citationAntonescu, C. R., Tschernyavsky, S. J., Decuseara, R., Leung, D. H. Y., Woodruff, J. M., Brennan, M. F., Bridge, J. A., Neff, J. R., Goldblum, J. R., & Ladanyi, M. (2001) · PubMed · Cited by 327
Dickson, M. A., Schwartz, G. K., Keohan, M. L., D’Angelo, S. P., Gounder, M. M., Chi, P., Antonescu, C. R., Landa, J., Qin, L.-X., Crago, A. M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0264 · Cited by 326
Infante, J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1248 · Cited by 317
Mir, O., Brodowicz, T., Italiano, A., Wallet, J., Blay, J.-Y., Bertucci, F., Chevreau, C., Piperno-Neumann, S., Bompas, E., Salas, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30507-1 · Cited by 280
Gebhard, S., Coindre, J.-M., Michels, J.-J., Terrier, P., Bertrand, G., Trassard, M., Taylor, S., Château, M.-C., Marquès, B., Picot, V., et al. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200205000-00006 · Cited by 256
Pleomorphic Liposarcoma: Clinicopathologic Analysis of 57 Cases
Hornick, J. L., Bosenberg, M. W., Mentzel, T., McMenamin, M. E., Oliveira, A. M., & Fletcher, C. D. M. (2004) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000135524.73447.4a · Cited by 251
Singer, S., Socci, N. D., Ambrosini, G., Sambol, E., Decarolis, P., Wu, Y., O'Connor, R., Maki, R., Viale, A., Sander, C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0584 · Cited by 250
Beane, J. D., Yang, J. C., White, D., Steinberg, S. M., Rosenberg, S. A., & Rudloff, U. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3732-4 · Cited by 243
Gronchi, A., Miceli, R., Colombo, C., Stacchiotti, S., Collini, P., Mariani, L., Sangalli, C., Redaelli, S., Sanfilippo, R. G., Fiore, M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr323 · Cited by 232
Kawai, A., Araki, N., Sugiura, H., Ueda, T., Yonemoto, T., Takahashi, M., Morioka, H., Hiraga, H., Hiruma, T., Kunisada, T., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70098-7 · Cited by 217
Mariani, O., Brennetot, C., Coindre, J.-M., Gruel, N., Ganem, C., Delattre, O., Stern, M.-H., & Aurias, A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.007 · Cited by 211
Liposarcoma: Molecular Genetics and Therapeutics
Conyers, R., Young, S., & Thomas, D. M. (2011) · Sarcoma · doi:10.1155/2011/483154 · Cited by 209
Demetri, G. D., Schöffski, P., Grignani, G., Blay, J., Maki, R. G., Tine, B. A. V., Alcindor, T., Jones, R. L., D’Adamo, D. R., Guo, M. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6605 · Cited by 180
Self-citationFunctional Copy-Number Alterations in Cancer
Taylor, B. S., Barretina, J., Socci, N. D., DeCarolis, P., Ladanyi, M., Meyerson, M., Singer, S., & Sander, C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003179 · Cited by 170 · cited 1×
“2-5 (containing RB1) has been described in up to 50% of patients.(11,27) Mutation or loss of TP53 is also seen, in contrast to other forms of LPS where TP53 alteration is uncommon.”
BackgroundGounder, M. M., Zer, A., Tap, W. D., Salah, S., Dickson, M. A., Gupta, A. A., Keohan, M. L., Loong, H. H., D’Angelo, S. P., Baker, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.6346 · Cited by 164
A phase II trial with rosiglitazone in liposarcoma patients
Debrock, G., Vanhentenrijk, V, Sciot, R., Debiec-Rychter, M., Oyen, R., & Van Oosterom, A. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601306 · Cited by 160
The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice
Pérez‐Losada, J., Pintado, B., Gutiérrez‐Adán, A., Flores, T., Bañares-González, B., del Campo, J. C., Martín-Martín, J. F., Battaner, E., & Sánchez-García, I. (2000) · Oncogene · doi:10.1038/sj.onc.1203572 · Cited by 149
Gronchi, A., Bui, B., Bonvalot, S., Pilotti, S., Ferrari, S., Hohenberger, P., Hohl, R. J., Demetri, G. D., Cesne, A. L., Lardelli, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr265 · Cited by 149
Kovatcheva, M., Liu, D. D., Dickson, M. A., Klein, M. E., O’Connor, R., Wilder, F. O., Socci, N. D., Tap, W. D., Schwartz, G. K., Singer, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3364 · Cited by 142
Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts
Fedele, M., Berlingieri, M. T., Scala, S., Chiariotti, L., Viglietto, G., Rippel, V., Bullerdiek, J., Santoro, M. M., & Fusco, A. (1998) · Oncogene · doi:10.1038/sj.onc.1201952 · Cited by 141
Forus, A., Weghuis, D. O., Smeets, D., Fodstad, Ø., Myklebost, O., & van Kessel, A. G. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870140103 · Cited by 137
Genomic landscape of liposarcoma
Kanojia, D., Nagata, Y., Garg, M., Lee, D. H., Sato, A., Yoshida, K., Sato, Y., Sanada, M., Mayakonda, A., Bartenhagen, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6464 · Cited by 136
Mode of action of trabectedin in myxoid liposarcomas
Giandomenico, S. D., Frapolli, R., Bello, E., Uboldi, S., Licandro, S. A., Marchini, S., Beltrame, L., Brich, S., Mauro, V., Tamborini, E., et al. (2013) · Oncogene · doi:10.1038/onc.2013.462 · Cited by 130
Pollack, S. M., Jungbluth, A. A., Hoch, B. L., Farrar, E. A., Bleakley, M., Schneider, D. J., Loggers, E. T., Rodler, E. T., Eary, J. F., Conrad, E. U., et al. (2012) · Cancer · doi:10.1002/cncr.27446 · Cited by 126
Self-citationde Jonge, M., de Weger, V. A., Dickson, M. A., Langenberg, M., Le Cesne, A., Wagner, A. J., Hsu, K., Zheng, W., Macé, S., Tuffal, G., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.005 · Cited by 124
Blay, J., Leahy, M. G., Nguyen, B. B., PATEL, S. R., Hohenberger, P., Santoro, A., Staddon, A. P., Penel, N., Piperno-Neumann, S., Hendifar, A. E., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.012 · Cited by 123
Patwardhan, P. P., Ivy, K. S., Musi, E., de Stanchina, E., & Schwartz, G. K. (2015) · Oncotarget · doi:10.18632/oncotarget.6547 · Cited by 121
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors
Wagner, A. J., Banerji, U., Mahipal, A., Somaiah, N., Hirsch, H., Fancourt, C., Johnson-Levonas, A. O., Lam, R., Meister, A. K., Russo, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7117 · Cited by 120
Baldini, E. H., Wang, D., Haas, R. L., Catton, C., Indelicato, D. J., Kirsch, D. G., Roberge, D., Salerno, K. E., Deville, C., Guadagnolo, B. A., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.02.013 · Cited by 119
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
Müller, C. R., Paulsen, E. B., Noordhuis, P., Pedeutour, F., Sæter, G., & Myklebost, O. (2007) · International Journal of Cancer · doi:10.1002/ijc.22643 · Cited by 119
Bill, K. L. J., Garnett, J., Meaux, I., Ma, X., Creighton, C. J., Bolshakov, S. V., Barrière, C., Debüssche, L., Lazar, A. J., Prudner, B. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1522 · Cited by 117
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma
Dickson, M. A., Mahoney, M. R., Tap, W. D., D’Angelo, S. P., Keohan, M. L., Tine, B. A. V., Agulnik, M., Horvath, L. E., Nair, J. S., & Schwartz, G. K. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw281 · Cited by 117
Mahmood, S., Agresta, S. V., Vigil, C. E., Zhao, X., Han, G., D’Amato, G. Z., Calitri, C. E., Dean, M. L., Garrett, C. R., Schell, M. J., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25843 · Cited by 115
Chibon, F., Mariani, O., Derré, J., Malinge, S., Coindre, J., Guillou, L., Lagacé, R., & Aurias, A. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00614-3 · Cited by 112
Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma
Demicco, E. G., Torres, K. E., Ghadimi, M. P., Colombo, C., Bolshakov, S. V., Hoffman, A., Peng, T., Bovée, J. V. M. G., Wang, W., Lev, D. C., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.148 · Cited by 97
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Jung, J., Lee, J. S., Dickson, M. A., Schwartz, G. K., Le Cesne, A., Varga, A., Bahleda, R., Wagner, A. J., Choy, E., de Jonge, M. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms12609 · Cited by 95
Pishvaian, M. J., Marshall, J. L., Wagner, A. J., Hwang, J., Malik, S. M., Cotarla, I., Deeken, J. F., He, A. R., Daniel, H., Halim, A., et al. (2012) · Cancer · doi:10.1002/cncr.27526 · Cited by 80
Guan, M., Fousek, K., Jiang, C., Guo, S., Synold, T., Xi, B., Shih, C., & Chow, W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3216 · Cited by 80
Ps, M., Sa, J., Cin, D., Sandberg, A., Ib, P., & Ma, C. (1991) · PubMed · Cited by 78
Chibon, F., Mariani, O., Derré, J., Mairal, A., Coindre, J., Guillou, L., Sastre‐Garau, X., Pédeutour, F., & Aurias, A. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20012 · Cited by 66
Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
Garg, M., Kanojia, D., Mayakonda, A., SAID, J. W., Doan, N., Chien, W., Ganesan, T. S., Chuang, L. S. H., Venkatachalam, N., Baloglu, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13485 · Cited by 63
Bender, A., Karbach, J., Neumann, A., Jäger, D., Al-Batran, S. E., Atmaca, A., Weidmann, E., Biskamp, M., Gnjatic, S., Pan, L. S., et al. (2007) · PubMed Central · Cited by 52
Asano, N., Yoshida, A., Mitani, S., Kobayashi, E., Shiotani, B., Komiyama, M., Fujimoto, H., Chuman, H., Morioka, H., Matsumoto, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14652 · Cited by 45
Functional Mapping of Receptor Tyrosine Kinases in Myxoid Liposarcoma
Negri, T., Virdis, E., Brich, S., Bozzi, F., Tamborini, E., Tarantino, E., Jocollé, G., Cassinelli, G., Grosso, F., Sanfilippo, R. G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2912 · Cited by 44
Burgess, M. A., Bolejack, V., Tine, B. A. V., Schuetze, S. M., Hu, J. S., D’Angelo, S. P., Attia, S., Priebat, D. A., Okuno, S. H., Riedel, R. F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.11008 · Cited by 40
MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas
Nair, J. S., & Schwartz, G. K. (2016) · Oncotarget · doi:10.18632/oncotarget.7335 · Cited by 36
Phase I study of nelfinavir in liposarcoma
Pan, J., Mott, M., Xi, B., Hepner, E., Guan, M., Fousek, K., Magnusson, R., Tinsley, R., Valdes, F., Frankel, P. H., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1961-4 · Cited by 33
Phase III Soft Tissue Sarcoma Trials: Success or Failure?
Lee, A. T. J., Pollack, S. M., Huang, P. H., & Jones, R. L. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0457-1 · Cited by 22
Self-citationDavidović, R., Sopta, J. P., Mandušić, V., Krajnović, M., Stanojević, M., Tulić, G., & Dimitrijević, B. (2013) · Medical Oncology · doi:10.1007/s12032-013-0682-9 · Cited by 13
Metadata
- Authors
- Lee, A. T. J., Thway, K., Huang, P. H., & Jones, R. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-01-10
- Volume
- 36
- Issue
- 2
- Pages
- 151-159
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2772838698
- Cited by
- 372
- References
- 70
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.